THAR Form 3: Executive Chairman LoPriore Discloses Options and Warrants
Rhea-AI Filing Summary
Vincent S. LoPriore filed an Initial Statement of Beneficial Ownership (Form 3) reporting his positions with Tharimmune, Inc. (THAR). He is listed as a Director, 10% owner and Executive Chairman. The filing shows 732,424 shares of common stock held indirectly through Gravitas Capital LP and several derivative instruments: a 100,000 stock option (exercise price $1.33, 50,000 vested at grant, remainder vests 08/04/2026), 337,838 Series A warrants ($1.29), 168,918 Series B warrants ($3.00) and 443,806 Common Stock Purchase Warrants ($2.03). The reporting person disclaims beneficial ownership except to extent of pecuniary interest.
Positive
- Director and Executive Chairman roles: The filing confirms LoPriore holds senior leadership and board positions, aligning governance and oversight.
- Significant economic stake: Indirect ownership of 732,424 common shares through Gravitas Capital LP signals committed insider investment.
- Equity incentives disclosed: Options and warrants provide alignment between management and potential future company performance.
Negative
- None.
Insights
TL;DR: A director and executive chairman holds a sizable indirect stake and multiple warrants/options, aligning management with significant ownership.
The Form 3 discloses that Vincent S. LoPriore is both a director and the Executive Chairman and holds a substantial indirect position through Gravitas Capital LP, representing 732,424 common shares. The presence of sizable warrants and options increases potential future share dilution but also indicates committed economic exposure via the reporting person's investment vehicle. The disclaimer limits direct beneficial attribution to LoPriore beyond pecuniary interest, a common structure when holdings are through an entity.
TL;DR: Reporting shows concentrated insider ownership and convertible instruments that could convert into material equity over time.
The filing lists a 100,000-share option (50,000 vested at grant) and combined warrants totaling 950,562 underlying shares across three warrant series with exercise prices from $1.29 to $3.00. If exercised, these instruments could meaningfully increase outstanding common shares, affecting ownership percentages. The Form 3 is a routine disclosure of initial beneficial ownership and does not include transaction dates beyond the event date of 04/09/2025 for reporting purposes.